Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 months.
Saved in:
| Title: | Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 months. |
|---|---|
| Authors: | Schnyder Ghamloush S; Moderna, Inc., Cambridge, MA, USA., Fanning S; The Alliance for Multispecialty Research, LLC, Knoxville, TN, USA., Essink B; Velocity Clinical Research, Omaha, NE, USA., Eder F; Velocity Clinical Research, Omaha, NE, USA., Snape MD; Moderna Biotech Manufacturing UK, Harwell Science and Innovation Centre, Didcot, UK., Stoszek SK; Moderna, Inc., Cambridge, MA, USA., Guo R; Moderna, Inc., Cambridge, MA, USA., Dhar R; Moderna, Inc., Cambridge, MA, USA., Righi V; Moderna, Inc., Cambridge, MA, USA., Morsy L; Moderna, Inc., Cambridge, MA, USA., Kapoor A; Moderna, Inc., Cambridge, MA, USA., El Asmar L; Moderna, Inc., Cambridge, MA, USA., Shaw CA; Moderna, Inc., Cambridge, MA, USA. |
| Source: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2557676. Date of Electronic Publication: 2025 Sep 15. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2164-554X |
|---|---|
| DOI: | 10.1080/21645515.2025.2557676 |
